Kendall Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.37M | Buy |
2,196
+80
| +4% | +$54.5K | 0.23% | 100 |
|
|
2026
Q1 | $1.63M | Sell |
2,116
-9
| -0.4% | -$6.89K | 0.34% | 77 |
|
|
2025
Q4 | $1.64M | Buy |
2,125
+1
| +0% | +$679 | 0.34% | 70 |
|
|
2025
Q3 | $1.19M | Sell |
2,124
-4
| -0.2% | -$2.26K | 0.27% | 94 |
|
|
2025
Q2 | $1.12M | Sell |
2,128
-84
| -4% | -$46.9K | 0.3% | 92 |
|
|
2025
Q1 | $1.4M | Sell |
2,212
-115
| -5% | -$79.1K | 0.41% | 64 |
|
|
2024
Q4 | $1.66M | Sell |
2,327
-20
| -0.9% | -$16.8K | 0.48% | 59 |
|
|
2024
Q3 | $2.47M | Sell |
2,347
-70
| -3% | -$77.9K | 0.76% | 38 |
|
|
2024
Q2 | $2.54M | Sell |
2,417
-70
| -3% | -$67.9K | 0.85% | 29 |
|
|
2024
Q1 | $2.39M | Sell |
2,487
-210
| -8% | -$200K | 0.82% | 31 |
|
|
2023
Q4 | $2.37M | Sell |
2,697
-75
| -3% | -$61.8K | 0.92% | 27 |
|
|
2023
Q3 | $2.28M | Sell |
2,772
-253
| -8% | -$199K | 1.01% | 24 |
|
|
2023
Q2 | $2.17M | Sell |
3,025
-55
| -2% | -$42.4K | 0.95% | 26 |
|
|
2023
Q1 | $2.53M | Buy |
3,080
+572
| +23% | +$431K | 1.22% | 18 |
|
|
2022
Q4 | $1.81M | Sell |
2,508
-10
| -0.4% | -$7.38K | 0.91% | 28 |
|
|
2022
Q3 | $1.74M | Sell |
2,518
-9
| -0.4% | -$5.67K | 1.01% | 24 |
|
|
2022
Q2 | $1.49M | Buy |
2,527
+234
| +10% | +$152K | 0.82% | 39 |
|
|
2022
Q1 | $1.6M | Buy |
2,293
+10
| +0.4% | +$6.33K | 0.77% | 37 |
|
|
2021
Q4 | $1.44M | Sell |
2,283
-72
| -3% | -$44.3K | 0.68% | 43 |
|
|
2021
Q3 | $1.43M | Sell |
2,355
-43
| -2% | -$26.7K | 0.77% | 41 |
|
|
2021
Q2 | $1.34M | Hold |
2,398
| – | – | 0.75% | 44 |
|
|
2021
Q1 | $1.14M | Buy |
2,398
+122
| +5% | +$59.4K | 0.7% | 46 |
|
|
2020
Q4 | $1.1M | Buy |
2,276
+110
| +5% | +$59.4K | 0.8% | 43 |
|
|
2020
Q3 | $1.21M | Sell |
2,166
-75
| -3% | -$45.5K | 1.05% | 33 |
|
|
2020
Q2 | $1.4M | Sell |
2,241
-70
| -3% | -$39.7K | 1.34% | 22 |
|
|
2020
Q1 | $1.13M | Sell |
2,311
-165
| -7% | -$68.1K | 1.28% | 25 |
|
|
2019
Q4 | $930K | Buy |
2,476
+483
| +24% | +$163K | 0.73% | 51 |
|
|
2019
Q3 | $553K | Buy |
1,993
+250
| +14% | +$74K | 0.49% | 70 |
|
|
2019
Q2 | $546K | Buy |
1,743
+414
| +31% | +$138K | 0.49% | 71 |
|
|
2019
Q1 | $546K | Buy |
1,329
+471
| +55% | +$194K | 0.52% | 63 |
|
|
2018
Q4 | $320K | Buy |
858
+189
| +28% | +$69.2K | 0.33% | 81 |
|
|
2018
Q3 | $270K | Buy |
+669
| New | +$255K | 0.23% | 98 |
|
Other funds holding REGN
Kendall Capital Management's REGN Position: Q2 2026 in Review
Kendall Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.8% in Q2 2026, buying an estimated $54.5K and bringing the position to 2,196 shares worth $1.37M. The position accounts for 0.23% of the portfolio, ranked #100.
Kendall Capital Management first reported a position in REGN in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.54M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Kendall Capital Management held 2,196 shares of Regeneron Pharmaceuticals worth $1.37M as of Q2 2026.
- Kendall Capital Management bought 80 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $54.5K.
- Regeneron Pharmaceuticals made up 0.23% of Kendall Capital Management's portfolio in Q2 2026, its #100 holding.
- Kendall Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Kendall Capital Management's Regeneron Pharmaceuticals position peaked at $2.54M in Q2 2024.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Kendall Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.